These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36896689)

  • 1. Erythrodermic Psoriasis Successfully Treated with Anti IL-17: A Case Series.
    Bernardini N; Skroza N; Proietti I; Mambrin A; Marchesiello A; Tolino E; Balduzzi V; Potenza C
    Acta Dermatovenerol Croat; 2021 Nov; 29(4):191-195. PubMed ID: 36896689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of erythrodermic psoriasis successfully treated with ixekizumab.
    Megna M; Gallo L; Balato N; Balato A
    Dermatol Ther; 2019 Mar; 32(2):e12825. PubMed ID: 30650216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological treatment for erythrodermic psoriasis.
    Dogra S; Mehta H
    Expert Opin Biol Ther; 2022 Dec; 22(12):1531-1543. PubMed ID: 36154361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of erythrodermic psoriasis successfully treated with guselkumab.
    Megna M; Ruggiero A; Camela E; Fabbrocini G; Marasca C
    Dermatol Ther; 2020 Mar; 33(2):e13238. PubMed ID: 31997488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of treatment strategies for erythrodermic psoriasis.
    Reynolds KA; Pithadia DJ; Lee EB; Liao W; Wu JJ
    J Dermatolog Treat; 2021 Feb; 32(1):49-55. PubMed ID: 31682547
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis.
    Saeki H; Nakagawa H; Ishii T; Morisaki Y; Aoki T; Berclaz PY; Heffernan M
    J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1148-55. PubMed ID: 25355284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ixekizumab as treatment of erythrodermic psoriasis.
    Trovato E; Orsini C; Russo F; Cortonesi G; Rubegni P
    Dermatol Ther; 2021 Mar; 34(2):e14868. PubMed ID: 33571383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of erythrodermic psoriasis with biologics: A systematic review.
    Carrasquillo OY; Pabón-Cartagena G; Falto-Aizpurua LA; Santiago-Vázquez M; Cancel-Artau KJ; Arias-Berrios G; Martín-García RF
    J Am Acad Dermatol; 2020 Jul; 83(1):151-158. PubMed ID: 32247872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two cases of refractory erythrodermic psoriasis effectively treated with secukinumab and a review of the literature.
    Liu LC; Jin XH; Sun C; Xia JX
    Dermatol Ther; 2021 Mar; 34(2):e14825. PubMed ID: 33527631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-IL17 therapies for psoriasis.
    Silfvast-Kaiser A; Paek SY; Menter A
    Expert Opin Biol Ther; 2019 Jan; 19(1):45-54. PubMed ID: 30500317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
    Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
    J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials.
    Cui L; Chen R; Subedi S; Yu Q; Gong Y; Chen Z; Shi Y
    Int Immunopharmacol; 2018 Sep; 62():46-58. PubMed ID: 29990694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J).
    Okubo Y; Mabuchi T; Iwatsuki K; Elmaraghy H; Torisu-Itakura H; Morisaki Y; Nakajo K
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):325-332. PubMed ID: 30317671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
    Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
    J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti IL-17 in psoriasis.
    Ly K; Smith MP; Thibodeaux Q; Reddy V; Liao W; Bhutani T
    Expert Rev Clin Immunol; 2019 Nov; 15(11):1185-1194. PubMed ID: 31603358
    [No Abstract]   [Full Text] [Related]  

  • 16. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
    Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
    Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Erythrodermic Psoriasis in Children with Secukinumab: A Case Report.
    Lu X; Wang W
    Clin Cosmet Investig Dermatol; 2023; 16():1977-1981. PubMed ID: 37539023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
    Bokor-Billmann T; Schäkel K
    J Dermatolog Treat; 2019 May; 30(3):216-220. PubMed ID: 30051725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythrodermic psoriasis successfully and rapidly treated with brodalumab: Report of two cases.
    Megna M; Fabbrocini G; Ferrillo M; Cinelli E
    Dermatol Ther; 2020 Nov; 33(6):e14351. PubMed ID: 32981222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ixekizumab 80 mg Every 2 Weeks Treatment Beyond Week 12 for Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis.
    Morita A; Okubo Y; Morisaki Y; Torisu-Itakura H; Umezawa Y
    Dermatol Ther (Heidelb); 2022 Feb; 12(2):481-494. PubMed ID: 34967916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.